FDA Appointees Withhold 3 Vaccine Safety Studies Covering Nearly 12 Million Recipients
Updated
Updated · The Guardian · May 12
FDA Appointees Withhold 3 Vaccine Safety Studies Covering Nearly 12 Million Recipients
2 articles · Updated · The Guardian · May 12
Two Covid-19 papers and Shingrix conference abstracts were pulled or blocked after FDA political appointees refused sign-off, despite completion by career scientists, peer review and journal acceptance.
7.5 million Medicare records showed only one clear new Covid-vaccine signal—anaphylaxis at about 1 per million Pfizer-BioNTech doses—while a 4.2 million-person study found rare febrile-seizure and myocarditis risks already listed on labels.
The Shingrix analysis confirmed a low Guillain-Barré risk already disclosed on the package insert, undercutting the agency's stated objection that the manuscripts drew conclusions unsupported by the data.
The suppression stands out because an unsubstantiated FDA memo linking 10 child deaths to Covid-19 vaccination was released, while reassuring findings were held back.
The episode raises broader transparency concerns as North America prepares for a 48-team World Cup starting June 11 amid measles resurgence and weakened CDC reporting channels.
While the FDA demands data integrity from companies, why were its own scientists' peer-reviewed vaccine studies suppressed?
If federal agencies can withdraw positive safety findings, what guarantees exist for reporting new, more dangerous health risks?
FDA Withholds Vaccine Safety Studies in 2026: Political Interference and the Erosion of Scientific Integrity
Overview
In May 2026, the FDA blocked the publication of its own vaccine safety studies, including those on shingles vaccines that had found the vaccines both effective and safe. Despite these reassuring results, the studies were withdrawn, and news of the decision surfaced quickly as related web pages were updated. This move, part of a broader shift in vaccine policy, raised immediate concerns about transparency and scientific integrity. The lack of clear explanation for withdrawing positive findings has sparked debate and worry among experts, highlighting the growing tension between public health leadership and the need for open scientific communication.